• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中药方剂治疗高脂血症的新方法。

Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia.

机构信息

Division of Life Science & Health, Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, China.

出版信息

J Ethnopharmacol. 2012 Mar 27;140(2):345-67. doi: 10.1016/j.jep.2012.01.027. Epub 2012 Jan 26.

DOI:10.1016/j.jep.2012.01.027
PMID:22306102
Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Traditional Chinese medicine (TCM) formulas have been widely used in China since ancient times to treat certain diseases (e.g., phlegm, dampness and blood stasis). Recently, the effects of these medicines have been increasingly demonstrated to be helpful for hyperlipidemic patients.

AIM OF THE STUDY

This manuscript aims to describe the scientific evidence for the efficacy of TCM and attempts to identify potential TCM formulas for treating hyperlipidemia.

MATERIALS AND METHODS

TCM formulas approved by the State Food and Drug Administration of China (SFDA) were sourced from the official SFDA website (http://www.sda.gov.cn/). Human and animal evidence for the hypolipidemic effects of herbs from TCM formulas were reviewed via the Internet (Elsevier, ACS, Wiley Online Library, SpringerLink, PubMed, Web of Science, CNKI, Baidu, and Google) and libraries up to October 31, 2011.

RESULTS

More than 50 TCM formulas have been used to treat hyperlipidemia. These herbs can primarily be grouped into three categories: (1) herbs promoting excretions, generally by reducing food retention, enhancing purgative effects, and promoting diuresis and choleretic effects, e.g., Fructus Crataegi (), Radix Polygoni Multiflori (), Semen Cassiae (), and Radix et Rhizoma Rhei (), Rhizoma alismatis (), and Herba Artemisiae Scopariae (); (2) herbs acting on the cardiovascular system, generally by improving blood circulation based on TCM theories, e.g., Radix Salviae Miltiorrhizae (), Radix Puerariae (), Rhizoma Chuanxiong (), Flos Carthami (), and Folium Nelumbinis (); and (3) herbs that have tonic effects, e.g., Fructus Lycii (), Radix Ginseng (), and Radix Astragali ().

CONCLUSIONS

Three basic approaches, including excretory function enhancement, cardiovascular system improvement, and tonic effect reinforcement, are emerging among TCM formulas for the treatment of hyperlipidemia. These approaches may be useful in controlling blood lipid levels, preventing cardiovascular complications, and adjusting bodily functions in hyperlipidemic patients. However, solid evidence of the efficacy of these treatments is required.

摘要

民族药理学相关性

自古以来,中药(TCM)配方就在中国被广泛用于治疗某些疾病(例如痰、湿和血瘀)。最近,这些药物的效果越来越被证明对高血脂患者有帮助。

研究目的

本文旨在描述 TCM 的疗效的科学证据,并试图确定治疗高血脂的潜在 TCM 配方。

材料和方法

从国家食品药品监督管理局(SFDA)官方网站(http://www.sda.gov.cn/)获取获得国家食品药品监督管理局批准的 TCM 配方。通过互联网(Elsevier、ACS、Wiley Online Library、SpringerLink、PubMed、Web of Science、CNKI、百度和谷歌)和图书馆检索截至 2011 年 10 月 31 日,对 TCM 配方的草药降血脂作用的人类和动物证据进行了综述。

结果

有 50 多种 TCM 配方用于治疗高血脂。这些草药主要可分为三类:(1)促进排泄的草药,一般通过减少食物滞留、增强泻下作用、促进利尿和利胆作用,如山楂()、何首乌()、决明子()、大黄()、泽泻()、薏苡仁()和青蒿();(2)作用于心血管系统的草药,一般通过基于中医理论改善血液循环,如丹参()、葛根()、川芎()、红花()、荷叶();和(3)具有滋补作用的草药,如枸杞()、人参()和黄芪()。

结论

TCM 配方治疗高血脂症的基本方法包括增强排泄功能、改善心血管系统和增强滋补作用。这些方法可能有助于控制血脂水平、预防心血管并发症并调节高血脂患者的身体功能。但是,需要有这些治疗方法疗效的可靠证据。

相似文献

1
Emerging approaches of traditional Chinese medicine formulas for the treatment of hyperlipidemia.中药方剂治疗高脂血症的新方法。
J Ethnopharmacol. 2012 Mar 27;140(2):345-67. doi: 10.1016/j.jep.2012.01.027. Epub 2012 Jan 26.
2
[Compatibility regularity of compound traditional Chinese medicine patents based on association principle and entropy method].基于关联原理和熵方法的中药复方专利配伍规律研究
Zhongguo Zhong Yao Za Zhi. 2015 Feb;40(3):550-5.
3
Diabetes is an inflammatory disease: evidence from traditional Chinese medicines.糖尿病是一种炎症性疾病:来自中药的证据。
Diabetes Obes Metab. 2011 Apr;13(4):289-301. doi: 10.1111/j.1463-1326.2010.01336.x.
4
[Data mining analysis of regularity of formulas containing Salviae Miltiorrhizae Radix et Rhizoma-Carthami Flos medicin pair in Dictionary of Chinese Medicine Prescription].[《中医方剂大辞典》中含丹参-红花药对方剂规律的数据挖掘分析]
Zhongguo Zhong Yao Za Zhi. 2016 Feb;41(3):528-531. doi: 10.4268/cjcmm20160328.
5
Can highly cited herbs in ancient Traditional Chinese medicine formulas and modern publications predict therapeutic targets for diabetes mellitus?古代中医药方剂和现代出版物中高引用的草药能否预测糖尿病的治疗靶点?
J Ethnopharmacol. 2018 Mar 1;213:101-110. doi: 10.1016/j.jep.2017.10.032. Epub 2017 Nov 2.
6
Lipid-lowering and antioxidant activities of Jiang-Zhi-Ning in Traditional Chinese Medicine.中药降脂宁的降脂和抗氧化活性。
J Ethnopharmacol. 2011 Apr 12;134(3):919-30. doi: 10.1016/j.jep.2011.01.048. Epub 2011 Feb 21.
7
[Study on drug properties and syndrome-symptom-formula-herb network of traditional Chinese medicine in treatment of effort angina pectoris based on data visualization].基于数据可视化的中医治疗劳力型心绞痛药物属性与证-症-方-药网络研究
Zhongguo Zhong Yao Za Zhi. 2020 Sep;45(18):4482-4489. doi: 10.19540/j.cnki.cjcmm.20200115.504.
8
[Evaluation on phytoestrogen effects of ten kinds of Chinese medicine including flos carthami].[包括红花在内的十种中药的植物雌激素效应评价]
Zhongguo Zhong Yao Za Zhi. 2007 Mar;32(5):436-9.
9
[Analysis of Chinese patent medicine prescriptions for Qi stagnation and blood stasis syndrome].[气滞血瘀证中成药方剂分析]
Zhongguo Zhong Yao Za Zhi. 2017 Jan;42(1):187-191. doi: 10.19540/j.cnki.cjcmm.20161222.005.
10
[Experimental study on two-way application of drugs with neutral property for promoting blood circulation and removing blood stasis on cold and heat blood stasis syndromes II].[中性活血化瘀药双向应用于寒热血瘀证的实验研究II]
Zhongguo Zhong Yao Za Zhi. 2013 Feb;38(4):605-10.

引用本文的文献

1
Comparative efficacy of eight traditional Chinese medicines combined with statins in the treatment of hyperlipidemia: a Bayesian network meta-analysis.八种中药联合他汀类药物治疗高脂血症的疗效比较:一项贝叶斯网络荟萃分析
Front Pharmacol. 2025 Aug 5;16:1614767. doi: 10.3389/fphar.2025.1614767. eCollection 2025.
2
Actin Dysregulation Mediates Nephrotoxicity of Cassiae Semen Aqueous Extracts.肌动蛋白失调介导决明子水提取物的肾毒性。
Toxics. 2024 Jul 30;12(8):556. doi: 10.3390/toxics12080556.
3
Bioactive Compounds Formulated in Phytosomes Administered as Complementary Therapy for Metabolic Disorders.
以植物药囊泡形式配制的生物活性化合物作为代谢紊乱的辅助疗法。
Int J Mol Sci. 2024 Apr 9;25(8):4162. doi: 10.3390/ijms25084162.
4
Efficacy of traditional Chinese medicine containing hawthorn for hyperlipidemia: a systematic review and meta-analysis.含山楂的中药治疗高脂血症的疗效:一项系统评价与Meta分析
Toxicol Res (Camb). 2024 Mar 11;13(2):tfae035. doi: 10.1093/toxres/tfae035. eCollection 2024 Apr.
5
HPTLC-Bioluminescent Bioautography Screening of Herbal Teas for Adulteration with Hypolipidemic Drugs.HPTLC-生物发光生物自显影筛选草药茶中是否掺有降血脂药物。
Biosensors (Basel). 2023 Mar 17;13(3):392. doi: 10.3390/bios13030392.
6
Hypolipidemic effect of ethanol extract from Chimonanthus nitens Oliv. leaves in hyperlipidemia rats via activation of the leptin/JAK2/STAT3 pathway.夏蜡梅叶乙醇提取物通过激活瘦素/JAK2/STAT3 通路对高脂血症大鼠的降血脂作用。
Mol Med. 2022 Dec 20;28(1):159. doi: 10.1186/s10020-022-00589-z.
7
Medicinal and edible plants in the treatment of dyslipidemia: advances and prospects.药用和食用植物治疗血脂异常:进展与展望
Chin Med. 2022 Sep 29;17(1):113. doi: 10.1186/s13020-022-00666-9.
8
The Mechanism of as a Treatment for Hyperlipidemia Based on Network Pharmacology and Experimental Validation.基于网络药理学和实验验证的[药物名称]治疗高脂血症的机制
Evid Based Complement Alternat Med. 2022 Apr 13;2022:5821829. doi: 10.1155/2022/5821829. eCollection 2022.
9
Mechanism of Alleviating Acquired Hyperlipidemia Induced by High-Fat Diet through Regulating Lipid Metabolism.通过调节脂质代谢减轻高脂饮食诱导的获得性高脂血症的机制
Nutrients. 2022 Feb 23;14(5):954. doi: 10.3390/nu14050954.
10
Pharmacokinetics, Tissue Distribution, and Excretion Characteristics of a Radix Polygoni Multiflori Extract in Rats.何首乌提取物在大鼠体内的药代动力学、组织分布及排泄特征
Front Pharmacol. 2022 Feb 21;13:827668. doi: 10.3389/fphar.2022.827668. eCollection 2022.